NEW YORK, June 15, 2017 /PRNewswire/ --
Today, DailyStockTracker.com reviews Endo International PLC (NASDAQ: ENDP), Teva Pharmaceutical Industries Ltd (NYSE: TEVA), Ionis Pharmaceuticals Inc. (NASDAQ: IONS), and Amarin Corp. PLC (NASDAQ: AMRN). Companies in the Drug Manufacturers space develop and sell medicines and vaccines for a wide range of medical uses. Access DailyStockTracker.com's complimentary reports for today's stocks line-up at:
Shares in Dublin, Ireland headquartered Endo International PLC saw a correction of 1.89%, ending Wednesday's trading session at $10.91. The stock recorded a trading volume of 5.95 million shares. The Company's shares have gained 3.51% over the last three months. The stock is trading 8.03% below its 50-day moving average. Moreover, shares of Endo International, which develops, manufactures, and distributes pharmaceutical products and devices worldwide, have a Relative Strength Index (RSI) of 39.84.
On June 08th, 2017, Endo International announced that it aware of the announcement by the US Food and Drug Administration requesting the Company to voluntarily withdraw OPANA® ER from the market. The Company is reviewing the request, and is evaluating the full range of potential options, as it determines the appropriate path forward.
On June 09th, 2017, research firm Stifel downgraded the Company's stock rating from 'Buy' to 'Hold' while revising its previous target price from $22 a share to $15 a share. Visit us today and access your complete report on ENDP for free at:
Petach Tikva, Israel headquartered Teva Pharmaceutical Industries Ltd's stock rose 0.49%, closing the day at $30.67 with a total trading volume of 4.82 million shares. The Company's shares are trading 0.11% below their 50-day moving average. Shares of the Company, which develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide, have an RSI of 56.82.
On June 12th, 2017, Teva Pharma announced the launch of generic Zetia[®1] (ezetimibe) tablets, 10 mg, in the US. Ezetimibe is a prescription medicine used to lower levels of total cholesterol and low-density lipoprotein cholesterol in the blood. It is for patients who cannot control their cholesterol levels by diet and exercise alone. The complimentary research report on TEVA can be accessed at:
On Wednesday, shares in Carlsbad, California headquartered Ionis Pharmaceuticals Inc. recorded a trading volume of 770,036 shares. The stock ended the day 0.51% higher at $50.80. The Company's shares have advanced 15.72% in the past month, 22.50% in the previous three months, and 6.21% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 12.88% and 21.96%, respectively. Furthermore, shares of Ionis Pharma, which focuses on developing drugs for patients with severe and rare diseases, have an RSI of 66.67.
On June 01st, 2017, Ionis Pharma announced that the European Commission has granted marketing authorization for SPINRAZA® (nusinersen) for the treatment of 5q spinal muscular atrophy (SMA). 5q SMA is the most common form of the disease, and represents approximately 95% of all SMA cases. SPINRAZA is the first approved treatment in the European Union for SMA, a leading genetic cause of death in infants that is marked by progressive, debilitating muscle weakness. Register for free on DailyStockTracker.com and download the research report on IONS at:
Dublin, Ireland-based Amarin Corp. PLC's stock finished yesterday's session flat at $2.96 with a total trading volume of 912,784 shares. The Company's shares are trading below their 50-day moving average by 2.93%. Shares of the Company, which focuses on the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the US, have an RSI of 44.83.
On June 12th, 2017, Amarin announced two, EPA-related data presentations unveiled this week at the American Diabetes Association® 77th Scientific Sessions in San Diego, CA: a post-hoc analysis of the ANCHOR study further characterizing the efficacy and safety of prescription pure EPA Vascepa® (icosapent ethyl) in the subgroup of statin-treated women with persistent high triglycerides and diabetes mellitus type 2; and an in vitro mechanistic study suggesting that EPA may be a potential strategy for reducing blood vessel cell dysfunction. Get free access to your research report on AMRN at:
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: (207)331-3313
Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA